SLGL
Sol-Gel Technologies Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$60.00
−7.03%Year over year
Reported trailing growth
- Revenue
- -92.5%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -35.9%
- EBITDA
- -73.8%
- EPS
- -68.5%
Three-year CAGR
- Revenue
- +70.9%
- EBITDA
- +36.9%
- EBIT
- +37.3%
- Net income
- +42.1%
- EPS
- +42.0%
- Free cash flow
- +102.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026